A recent study by the ICMR National Centre for Disease Informatics and Research warns of a 5.6% annual increase in Indian breast cancer cases, driven by various risk factors.
Zosia Miedzybrodzka has been appointed an Officer of the Order of the British Empire (OBE) for her services to genetics ...
In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.
The Manila Times on MSN
HPV vaccine developers, hybrid rice innovators top 2025 VinFuture Prize
DECADES of virology research that yielded the human papillomavirus (HPV) vaccine and identified the virus as a primary cause ...
Angelina Jolie Suffers 'Brutal' Trolling Over Mastectomy-Baring Photoshoot: 'People Are Twisting It'
Angelina Jolie has shockingly faced a torrent of callous online abuse after boldly baring the scars from her double ...
Use of MHT following menopause is not associated with an increased risk for breast cancer among BRCA1 and BRCA2 carriers.
Angelina Jolie shows mastectomy scars to spotlight breast health on TIME France. The Oscar-winning actor appears on the first ...
Cover Media US on MSN
News of the week: Angelina Jolie displays mastectomy scars for first time
The Oscar-winning actress underwent a preventative double mastectomy in February 2013 after learning that she had a high risk of developing breast cancer due to the defective BRCA1 gene. In a preview ...
Cedars Sinai gets 30M to establish a specialized BRCA cancer center focusing on research, diagnosis, and treatment in Los Angeles.
The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...
The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...
The FDA converted the PARP inhibitor's 2020 accelerated approval to full approved based on results from the Phase III TRITON3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results